Enhancement of Antiviral CD8(+) T-Cell Responses and Complete Remission of Metastatic Melanoma in an HIV-1-Infected Subject Treated with Pembrolizumab

Background: Pembrolizumab is an immune checkpoint inhibitor against programmed cell death protein-1 (PD-1) approved for therapy in metastatic melanoma. PD-1 expression is associated with a diminished functionality in HIV-1 specific-CD8(+) T cells. It is thought that PD-1 blockade could contribute to...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Clin Med
Prif Awduron: Blanch-Lombarte, Oscar, Gálvez, Cristina, Revollo, Boris, Jiménez-Moyano, Esther, Llibre, Josep M., Manzano, José Luís, Boada, Aram, Dalmau, Judith, E. Speiser, Daniel, Clotet, Bonaventura, G. Prado, Julia, Martinez-Picado, Javier
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: MDPI 2019
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6947580/
https://ncbi.nlm.nih.gov/pubmed/31805700
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm8122089
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg